Skip to main navigation Skip to search Skip to main content

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase III Study with a Long-Term OpenLabel Extension to Evaluate the Efficacy and Safety of TRM-201 (Rofecoxib) in Patients with Hemophilic Arthropathy

Project: Research

Project Details

StatusFinished
Effective start/end date05/31/22 → 12/31/25

Funding

  • IQVIA Incorporated: $15,100.00